Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential Phase I and Phase II clinical trial
- 29 January 2009
- Vol. 27 (5) , 786-791
- https://doi.org/10.1016/j.vaccine.2008.11.003
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Safety and Immunogenicity of a Baculovirus-Expressed Hemagglutinin Influenza VaccineJAMA, 2007
- Medical economics in the field of influenza—past, present and futureVirus Research, 2004
- Influenza Vaccine — Outmaneuvering Antigenic Shift and DriftNew England Journal of Medicine, 2004
- Mortality Associated With Influenza and Respiratory Syncytial Virus in the United StatesJAMA, 2003
- Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and childrenVaccine, 2001
- Epidemiology and pathogenesis of influenzaJournal of Antimicrobial Chemotherapy, 1999
- InfluenzaPharmacoEconomics, 1999
- Development of a mammalian cell (Vero) derived candidate influenza virus vaccineVaccine, 1998
- The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working populationOccupational Medicine, 1998
- Impact of Influenza on Mortality in Relation to Age and Underlying Disease, 1967–1989International Journal of Epidemiology, 1993